Purdue reportedly reaches tentative opioids settlement

12 September 2019
purduebig

According to media reports, privately-owned Purdue Pharma has reached a preliminary proposed settlement with multiple state, local and tribal governments that accuse the company of helping to drive the opioid crisis. But many attorney generals are opposing it and say the fight is not over.

The billionaire Sackler family, which owns the company that markets the painkiller OxyContin,  has offered $3 billion plus a portion of future revenue from drug sales, as well as another $1.5 billion pending the sale of an international company the family owns, Mundipharma - which sells the products outside the USA, a person familiar with the ongoing settlement negotiations told CNN.

Pennsylvania Attorney General Josh Shapiro vowed Wednesday the case was "far from over." In a statement obtained by CNN, he said: "This apparent settlement is a slap in the face to everyone who has had to bury a loved one due to this family's destruction and greed. It allows the Sackler family to walk away billionaires and admit no wrongdoing."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical